UNIGE document Scientific Article
previous document  unige:101812  next document
add to browser collection

Serelaxin for infant heart failure in congenital dilated cardiomyopathy

Published in Cardiology in the Young. 2018
Abstract Serelaxin has been studied in trials in adults with acute heart failure, but not in children. We report the first compassionate use of serelaxin in an infant. A 6-month-old girl with dilated cardiomyopathy was placed on extracorporeal membrane oxygenation following cardiac arrest unresponsive to medical treatment. Extracorporeal membrane oxygenation weaning failed despite maximal ino-dilator therapy. During the 48-hour infusion of serelaxin, we observed marked improvement in brain natriuretic peptide, left ventricular systolic function, and dilatation. The patient was successfully weaned from extracorporeal membrane oxygenation 24 hours later. The child died after a second extracorporeal membrane oxygenation run owing to sepsis.
Keywords CHDHeart failureinotropic/vasoactive drugs
PMID: 29332614
Full text
Article (Published version) (447 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Research groups Dysfonctions cardio-pulmonaires et cérébrales (278)
Maladies pulmonaires aigues et pathologies cardiaques congénitales (697)
(ISO format)
MYERS, Patrick Olivier, BORDESSOULE, Alice, TISSOT-DAGUETTE, Cécile. Serelaxin for infant heart failure in congenital dilated cardiomyopathy. In: Cardiology in the Young, 2018. doi: 10.1017/S1047951117002797 https://archive-ouverte.unige.ch/unige:101812

339 hits

1 download


Deposited on : 2018-01-31

Export document
Format :
Citation style :